Balversa – Talk Bio

Actionable Insights Powered by AI

Tyra Biosciences Unveils Early Data for FGFR3 Inhibitor, TYRA-300, in Challenge to J&J’s Balversa

6 months ago talkbio0Tagged Balversa, Carcinoma, Transitional Cell, concerns, Effectiveness, FGFR3 protein, human, Inhibitor, J&J, Malignant neoplasm of urinary bladder, Safety, Tyra Biosciences, TYRA-300

Tyra Biosciences, TYRA-300, Balversa, J&J, bladder cancer, urothelial carcinoma, FGFR3 inhibitor, safety concerns, efficacy data

Johnson & Johnson Presents Updated Findings on Balversa Treatment for Bladder Cancer

12 months ago talkbio0Tagged Balversa, Carcinoma, Transitional Cell, Clinical Data, Fibroblast Growth Factor Receptors, Inhibitor, Johnson and Johnson, Malignant neoplasm of urinary bladder

Johnson & Johnson, Balversa, bladder cancer, clinical data, FGFR inhibitor, targeted therapy, urothelial carcinoma.